Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials

PURPOSE: The present meta-analysis study was performed to identify the potential cardiotoxicity risks when using Vascular Endothelial Growth Factor Receptor Tyrosine kinase inhibitors (VEGFR-TKIs) as anticancer drugs in patients with solid tumors. METHODS: Pubmed, Embase, the Cochrane Central Regist...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wanting, Ding, Mingfu, Li, Xiaohua, Zhou, Xiaohan, Zhu, Qing, Varela-Ramirez, Armando, Yi, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236482/
https://www.ncbi.nlm.nih.gov/pubmed/33725154
http://dx.doi.org/10.1007/s00432-021-03521-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236482/
https://www.ncbi.nlm.nih.gov/pubmed/33725154
http://dx.doi.org/10.1007/s00432-021-03521-w

Ejemplares similares